Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid Leukemia

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d4668889e174">The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia. </p>

Related collections

Author and article information

Contributors

Rodrigo T. Calado: (View ORCID Profile)

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: April 21 2022

Publication date (Print): April 21 2022

Volume: 386

Issue: 16

Pages: 1519-1531

Affiliations

[1 ]From Hospital Universitari i Politècnic La Fe, Valencia (P.M.), and Hospital Universitario Germans Trias i Pujol–Institut Català d’Oncologia Badalona, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona (S.V.) — both in Spain; Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse (C.R.), and Institut Gustave Roussy, Villejuif (S.B.) — both in France; Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne,...

Article

DOI: 10.1056/NEJMoa2117344

PubMed ID: 35443108

SO-VID: 351a8a2e-7554-4e38-8c5f-a63b0ed3574c

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 106

See all cited by

- Version 1

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Read this article at